Clinical Trial Update: Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b [Phase 3]

View source ↗

Summary

Open-label Phase 3 study evaluating the efficacy and safety of the elbasvir/grazoprevir fixed-dose combination in adults with chronic hepatitis C genotype 1b (w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Liver Cirrhosis
• Liver Fibrosis
• Metabolic Syndrome

Drugs mentioned

• Zepatier (elbasvir/grazoprevir)

Snippet

Sponsor: Institute Of Cardiology & Internal Diseases, Kazakhstan | Conditions: Chronic Hepatitis C Genotype 1B, Metabolic Syndrome | Phase 3 | Status: UNKNOWN